ATLANTA, April 29, 2013 (GLOBE NEWSWIRE) -- novoGI Inc. today announced that its nitinol compression anastomosis technology and novoGI™ ColonRing device were the focus of several scientific sessions at recent gastrointestinal (GI) surgery meetings in France, the 16th Journées de Chirurgie Digestive held in Bordeaux and the Journées de Chirurgie Digestive de Beaujon in Paris.
Sessions by leading colorectal surgeons focused on recently published data for successful outcomes for novoGI™ ColonRing in terms of low leak rates of 1.9% - 4% and healing processes for low anterior resection (LAR) procedures, training methods, and ease of use for the surgical technique.
Prof Eric Rullier, MD (University Hospital, Bordeaux, France) led the session novoGI Symposium Anastome colorectale par compression. During the same podium session, Prof Paul-Antoine Lehur, MD (CHU de Nantes, Nantes, France) presented the World Congress of Compression Anastomosis (WCCA), its organization and goals, focusing on training methods. At the Paris meeting, Prof Yves Panis, MD, PhD (Beaujon Hospital, Clichy, France) demonstrated the surgical technique using the novoGI™ ColonRing compression anastomosis device in an LAR procedure which was broadcast live to participants.
"We are very excited about the enthusiastic response to novoGI's compression anastomosis technology – the clinical results and the actual surgical technique – presented at these scientific meetings as well as last month's annual French congress of 4,000 gastroenterologists, Journées Francophones d'Hepato-gastroeneterologie et d'Oncologies Digestive (JFHOD), which included 4,000 medical professionals," commented Jean-Paul Durand, novoGI Corporate Vice President and General Manager for Europe.
"The success of recent events in France demonstrates novoGI's growing global presence," novoGI President and Chief Executive Officer, Gavriel D. Meron noted. "As we progress through this week's sessions of the American Society of Colon & Rectal Surgeons (ASCRS) 2013 Annual Meeting in Phoenix, Arizona, we look forward to next week's scientific symposium on novoGI's nitinol compression anastomosis in Munich at the regional German conference of 8,000 surgeons."
novoGI is focused on providing an expanding range of solutions for GI disease management through a globally branded, high quality, market driven company. The US headquarters are in Atlanta, Georgia; research, development and manufacturing facilities in Netanya, Israel; and its European headquarters are near Paris, France. The company's website is www.novoGI.com.
NOVOGI, the NOVOGI logo, the GI logo, and DEFINING THE FUTURE are trademarks and/or registered trademarks of novoGI Inc.